Data show value of antibody therapies for some COVID patients

26 April 2024
biotech_research_test_tube_big

British pharma major AstraZeneca (LSE: AZN) has presented new data from the INFORM and COVIDRIVE real-world studies at the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID).

The results show the significant burden of COVID-19 on immunocompromised patients, compared to the general population.

Data from INFORM show that, despite receiving at least four vaccinations, many such individuals remain poorly protected against the virus.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology